Klin Farmakol Farm. 2015;29(2):80-83

Advantages of transdermal forms of hormone replacement therapy from the perspective of a gynaecologist

Peter Koliba
Gynartis, s. r. o., Ostrava &ndash, Vřesina

The review article on the issue of menopausal hormone therapy focuses on transdermal forms of treatment. In the period of menopause,

many metabolic and psychological changes occur that are part of the aging process and can negatively affect the quality

of life of women. The mainstay of the treatment of acute vegetative syndrome is hormone replacement therapy (HRT) and, more

recently, menopausal hormone therapy (MHT). In the Czech Republic, a number of medications for HRT in various dosage forms are

available on the market. This article describes the advantages of transdermal dosage forms in the treatment of climacteric syndrome.

The authors underline the main rules of this treatment on the basis of the most recent advice according to the 2013 International

Menopause Society recommendations.

replacement therapy.

Keywords: menopause, climacteric syndrome, hormone replacement therapy, menopausal hormone therapy, transdermal hormone

Published: July 1, 2015  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Koliba P. Advantages of transdermal forms of hormone replacement therapy from the perspective of a gynaecologist. Klin Farmakol Farm. 2015;29(2):80-83.
Download citation

References

  1. Fait T. Klimakterická medicína, Edice: Farmakoterapie pro praxi, Maxdorf 2013, ISBN 978-80-7345-342-8.
  2. Vlček J, Vytřísalová M, a kol. Klinická farmacie II, Grada Publishing 2014, ISBN 978-247-4532-9.
  3. Beral V, Banks E, et al. Evidence from randomised trials on the long-therm effects of hormone replacement therapy, The Lancet 2002; 360: 942-944. Go to original source... Go to PubMed...
  4. Kubíková D. Menopauzální symptomy a hormonální substituční terapie, Prakt. Lékáren. 2014; 10(2): 68-73.
  5. Vráblík M. Kardiovaskulární riziko a hormonální substituční léčba v menopauze. Interní medicína pro praxi 2009; 11(5): 207-210.
  6. Kim JM, Kim TH, et al. Postmenopausal hypertension and sodium sensitivity, J Menopausal Med, 2014; 20(1): 1-6. Go to original source... Go to PubMed...
  7. Ruiz AD, et al. The effectiveness of sublingual and topical compounded biodentical hormone replacement therapy in postmenopausal women: an observation alcohort study, Int J Pharm Conpd. 2014; (1): 70-77.
  8. Liu B. Is transdermal menopausal hormone therapy a safer option than oral therapy? CMAJ. 2013; 185(7): 549-550. Go to original source... Go to PubMed...
  9. Pentravan, https://cz.fagron.com/cs/produktove-inovace/pentravanr, leden 2014.
  10. Polonini HC, et al. Evaluation of percutaneous absorption performance for human female sexual steroids in topentravancream., Int J Pharm Compd 2014; 18(4): 332-340.
  11. Eisenberger A, et al. Hormone replacement therapy and venous tromboembolism: J Steroid Biochem Mol Biol. 2014; 142: 76-82. Go to original source... Go to PubMed...
  12. L'Hermite M. HRT optimization, using transdermal estradiol plus micronised progesterone a safer HRT, Climacteric 2013; 16(Suppl 1): 44-53. Go to original source... Go to PubMed...
  13. Sumino H. Investitation of atherosclerosis in postmenopausal women: alteration of atherosclerosis-associated factors and vascular atherosclerosis by oral and transdermal estrogen replacement, Rinsho Byori, 2013; 61(3): 256-262. Go to PubMed...
  14. Machens K, et al. Issues to debate on the Women's Health Initiative (WHI) study. Hormone replacement therapy: an epidemiological dilemma? Hum Reprod: 2003; 18(10): 1992-2010. Go to original source... Go to PubMed...
  15. Park S, Yang MJ. Effective Anti-Aging strategies in an Era of Super Aging, J Menopausal Med. 2014; 20(3): 85-89. Go to original source... Go to PubMed...
  16. Grady D, Applegate W, et al. Heart and Estrogen/progestin Replacement Study (HERS): design, methods and baseline characteristics, Control Clin Trials. 1998; 19(4): 314-335. Go to original source... Go to PubMed...
  17. Siegelová V. První komplexní řešení hormonální substituční léčby v transdermální formě. Medicína, 2000; 7: 19.
  18. T. J. de Villiers, et al. Updated 2013 International Menopause Society recommendations on menopausal hormone therapy and preventive strategies for midlife health. Climacteric 2013; 16: 316-337. Go to original source... Go to PubMed...
  19. Český statistický úřad: na http://www.czso.cz/csu/redakce.nsf/i/obyvatelstvo_lide.
  20. Koliba P. Aktualizované doporučení IMS k hormonální léčbě. Lékařské listy. 2012; 6: 15-17. Volně přeloženo z CLIMACTERIC 2011; 14: 302-320. Go to original source... Go to PubMed...
  21. Fait T. Klimakterium a hormonální substituční terapie. Moderní babictví [2003]. 2004; 3: 3-12. ISSN: 1214-5572.
  22. Fait T, Donát J, Jeniček J, et al. Doporučení pro hormonální substituční terapii v postmenopauze. Čes Gynek 2010; 75(2): 109-110.
  23. Harman SM, et al. KEEPS: The Kronos Early Estrogen Prevention Study. Climacteric, 2005; 8(1): 3-12. Go to original source... Go to PubMed...
  24. Donát J. Hormonální substituční terapie, DoMeNa, Hradec Králové 1999: 75.
  25. SÚKL www.sukl.cz, (Online) 1 2015, http://www.sukl.cz/modules/medication/search.php.




Clinical Pharmacology and Pharmacy

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.